

ATHENA-1 (NCT05685173)

PHASE 1 ENROLLING

Study of investigational REGN5837 + odronextamab in patients with B-cell non-Hodgkin lymphomas



Primary Objective: evaluate the safety, tolerability, and antitumor activity of REGN5837 with odronextamab in patients with aggressive B-NHL



PATIENTS WITH B-NHL (N≈91)

OPEN LABEL INTERVENTION

**Step-up dosing schedule of
REGN5837 (IV) + odronextamab (IV)**

Primary Endpoints

Safety and tolerability
Recommended Phase 2 dose

Key Secondary Endpoints

Pharmacokinetics
Immunogenicity
Objective response rate^{a,b}

Progression-free survival^b
Duration of response^b
Overall survival



FIND OUT MORE

Scan here to find out more about this study at <https://clinicaltrials.gov/ct2/show/NCT05685173>

This information is intended for investigators interested in open clinical trials.
The use of REGN5837 + odronextamab described herein is investigational and has not been evaluated by any regulatory authority.

^aAccording to the Lugano Classification of response in malignant lymphoma. ^bBased on investigator assessment.
IV, intravenous; N, number of patients.

REGN5837

An Investigational CD22xCD28 Bispecific Antibody

Simultaneously engages CD22 on cancer cells with CD28 on T cells¹

ODRONEXTAMAB

An Investigational CD20xCD3 Bispecific Antibody

Simultaneously engages CD20 on malignant B cells and CD3 on cytotoxic T cells¹SELECTED INCLUSION CRITERIA^a

Documented CD20+ aggressive B-NHL with disease progression following at least 2 prior lines of therapy containing an anti-CD20 antibody and an alkylating agent



Adequate bone marrow, renal, and hepatic function



Measurable disease on cross sectional imaging



ECOG PS 0 or 1

SELECTED EXCLUSION CRITERIA^a

Prior allogeneic stem cell or solid organ transplantation



Prior treatment with anti-CD20xCD3 antibodies



Anti-lymphoma treatment within 5 half-lives or 14 days of first administration of study drug



Radiotherapy within 14 days of first administration of study drug



Diagnosis of MCL or primary CNS lymphoma



Allergy or hypersensitivity to both allopurinol and rasburicase



For more information, visit www.clinicaltrials.gov or please call 844 REGN-MID.
NCT05685173
<https://clinicaltrials.gov/ct2/show/NCT05685173>

This information is intended for investigators interested in open clinical trials.

The use of REGN5837 + odronextamab described herein is investigational and has not been evaluated by any regulatory authority.

^aInclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on [clinicaltrials.gov](https://www.clinicaltrials.gov) for complete details.

B-NHL, B-cell non-Hodgkin lymphoma; CD, cluster of differentiation; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; MCL, mantle cell lymphoma.

1. Wei J, et al. *Sci Transl Med*. 2022;14:eabn1082. 2. Smith EJ et al. *Sci Rep*. 2015;5:17943.

Current per [clinicaltrials.gov](https://www.clinicaltrials.gov) as of November 7, 2023.

Odronextamab-EM-0010 November 2023.

©2023 Regeneron Pharmaceuticals, Inc. All rights reserved.